BRMS1 Polyclonal Antibody, FITC Conjugated
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-8686R-FITC-100uL |
| Product Name | BRMS1 Polyclonal Antibody, FITC Conjugated |
| Applications |
WB
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Reactivity | Human, Mouse, Rat |
| Predicted Reactivity | Dog, Pig, Horse |
| Specifications | |
| Conjugation | FITC |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human BRMS1 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Subcellular location | Cytoplasm, Nucleus |
| Synonyms | Breast cancer metastasis suppressor 1; Breast cancer metastasis-suppressor 1; BRMS-1; BRMS1_HUMAN; DKFZp564A063; MGC95128; AV003220; AW554636. |
| Background | Breast cancer metastasis-suppressor 1 (BRMS1) is 246 amino acid protein that acts as a mediator of metastasis suppression in several types of cancer including ovarian, lung, bladder, and murine mammary. BRMS1 mRNA is expressed in various tissues, including ovary, prostate, testis, and colon, but the protein is primarily detected in term placenta. BRMS1 suppresses metastasis without inhibiting tumorigenicity by modifying several metastasis-associated phenotypes. BRMS1 may participate in transcriptional regulation by binding to the mSin3/histone deacetylase complex. The expression of BRMS1 in certain cells increases connexin Cx43 expression and reduces connexin Cx32 expression. This produces a gap junction that increases intercellular communication, similar to those found in normal breast tissue. BRMS1 is stabilized by Hsp90 and may inhibit NF-_B activity. |
| Application Dilution | |
| WB | 1:300-5000 |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |
Frequently asked questions
Which applications is BRMS1 Polyclonal Antibody, FITC Conjugated (bs-8686R-FITC) validated for, and at what dilution?
bs-8686R-FITC is validated for WB (1:300-5000); IF(IHC-P) (1:50-200); IF(IHC-F) (1:50-200); IF(ICC) (1:50-200). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
Which species does BRMS1 Polyclonal Antibody, FITC Conjugated (bs-8686R-FITC) react with?
Tested reactivity: Human, Mouse, Rat. Predicted reactivity (expected from sequence homology but not yet tested): Dog, Pig, Horse.
How should bs-8686R-FITC be stored?
Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise BRMS1 Polyclonal Antibody, FITC Conjugated (bs-8686R-FITC)?
KLH conjugated synthetic peptide derived from human BRMS1
What are the excitation and emission wavelengths of the FITC conjugate (bs-8686R-FITC)?
FITC on bs-8686R-FITC: excitation / emission 494nm/518nm.
